TABLE 1 from Synergy of EGFR and AURKA Inhibitors in KRAS-mutated Non–small Cell Lung Cancers

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1TABLE 1 from Synergy of EGFR and AURKA Inhibitors in <i>KRAS</i>-mutated Non–small Cell Lung Cancers2024
2. 2Figure S1 from Synergy of EGFR and AURKA Inhibitors in <i>KRAS</i>-mutated Non–small Cell Lung Cancers2024
3. 3Figure S4 from Synergy of EGFR and AURKA Inhibitors in <i>KRAS</i>-mutated Non–small Cell Lung Cancers2024
4. 4FIGURE 2 from Synergy of EGFR and AURKA Inhibitors in <i>KRAS</i>-mutated Non–small Cell Lung Cancers2024
5. 5FIGURE 1 from Synergy of EGFR and AURKA Inhibitors in <i>KRAS</i>-mutated Non–small Cell Lung Cancers2024